DB17303InvestigationalVaccines
Leuvectin (formerly known as VCL-1102) is a component of gene therapy along with cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE/DOPE).
- Also known as
- DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2
- Code names
- VCL-1102
What you can answer from here — as of April 23, 2025
Which companies are running trials of Leuvectin, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account